Matteo Bellone

List of Publications by Year in Descending Order

110 papers	3,258 citations	31 h-index	54 g-index
127 ext. papers	3,836 ext. citations	7.7 avg, IF	4.98 L-index

#	Paper	IF	Citations
110	Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15-16, 2020.. *Cancer Immunology, Immunotherapy*, **2022**, 1	7.4	
109	The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma.. *Frontiers in Immunology*, **2022**, 13, 845422	8.4	0
108	Development and Validation of [18f](2 S,4 R)-4-Fluoroglutamine in Multiple Myeloma Mouse Models. *Blood*, **2021**, 138, 2674-2674	2.2	
107	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	
106	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. *Science*, **2021**, 374, 216-224	33.3	28
105	[F](2,4)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma. *Frontiers in Oncology*, **2021**, 11, 760732	5.3	2
104	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. *Cytokine and Growth Factor Reviews*, **2021**, 59, 1-8	17.9	2
103	A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer. *Cancer Biology and Medicine*, **2021**,	5.2	0
102	CD4+ T cells sustain aggressive chronic lymphocytic leukemia in E□TCL1 mice through a CD40L-independent mechanism. *Blood Advances*, **2021**, 5, 2817-2828	7.8	0
101	Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. *Microbiology and Molecular Biology Reviews*, **2020**, 84,	13.2	17
100	Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer. *Frontiers in Immunology*, **2020**, 11, 565470	8.4	21
99	Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis. *Frontiers in Immunology*, **2020**, 11, 1820	8.4	8
98	Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models. *Clinical Cancer Research*, **2020**, 26, 6387-6398	12.9	10
97	ACE polymorphisms and COVID-19-related mortality in Europe. *Journal of Molecular Medicine*, **2020**, 98, 1505-1509	5.5	21
96	Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy. *Resistance To Targeted Anti-cancer Therapeutics*, **2019**, 173-221	0.3	1
95	Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival **2019**, 7, 201		5
94	Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold. *Small*, **2019**, 15, e1903462	11	10

93	CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism. *Blood*, **2019**, 134, 683-683	2.2	
92	[18f]-(2S,4R)-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma. *Blood*, **2019**, 134, 5542-5542	2.2	
91	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?. *Neoplasia*, **2019**, 21, 93-105	6.4	22
90	PD-L1 Expression and CD8 T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. *European Urology Focus*, **2019**, 5, 192-196	5.1	60
89	Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization. *Cancer Research*, **2018**, 78, 2654-2668	10.1	22
88	Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. *Clinical Cancer Research*, **2018**, 24, 2171-2181	12.9	25
87	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. *Cell Reports*, **2018**, 22, 3006-3020	10.6	32
86	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. *Frontiers in Immunology*, **2018**, 9, 1786	8.4	14
85	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. *Nature Communications*, **2018**, 9, 4832	17.4	78
84	Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. *Blood*, **2017**, 129, 3440-3451	2.2	40
83	Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-*Molecular Cancer Therapeutics*, **2017**, 16, 365-375	6.1	7
82	Fatty is not that bad: feeding short-chain fatty acids to restrain autoimmunity. *Cellular and Molecular Immunology*, **2017**,	15.4	5
81	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). *Cytokine and Growth Factor Reviews*, **2017**, 36, 1-3	17.9	0
80	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. *Cytokine and Growth Factor Reviews*, **2017**, 36, 17-24	17.9	18
79	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNF Expression and Empower Adoptive Cell Therapy for Solid Tumors. *Cancer Research*, **2017**, 77, 658-671	10.1	22
78	Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients. *Cancer Research*, **2016**, 76, 1781-91	10.1	19
77	Targeting vasculogenesis to prevent progression in multiple myeloma. *Leukemia*, **2016**, 30, 1103-15	10.7	37
76	Long non-coding RNAs as novel therapeutic targets in cancer. *Pharmacological Research*, **2016**, 110, 131-138	7.2	60

75	"Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013. *Cancer Immunology, Immunotherapy*, **2015**, 64, 131-5	7.4	
74	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. *OncoImmunology*, **2015**, 4, e1008850	7.2	19
73	Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation. *Cancer Research*, **2015**, 75, 2095-108	10.1	76
72	Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. *Oncogene*, **2015**, 34, 2094-102	9.2	59
71	Autoimmune Disease: Pathogenesis **2015**, 1-9		3
70	Immunosuppression via Tenascin-C. *Oncoscience*, **2015**, 2, 667-8	0.8	6
69	Induction of T-cell memory by a dendritic cell vaccine: a computational model. *Bioinformatics*, **2014**, 30, 1884-91	7.2	27
68	Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads. *International Journal of Cancer*, **2014**, 135, 1265-76	7.5	39
67	A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. *OncoImmunology*, **2014**, 3, e963406	7.2	19
66	Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. *Blood*, **2014**, 124, 4719-4719	2.2	
65	Angiogenesis Associated with Alterations of the Bone Marrow Microenvironment Predicts Multiple Myeloma Progression to Symptomatic Disease in Mice and Humans. *Blood*, **2014**, 124, 5678-5678	2.2	
64	Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. *Cancer Research*, **2013**, 73, 3545-54	10.1	16
63	Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors. *Stem Cells Translational Medicine*, **2013**, 2, 678-89	6.9	18
62	Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. *Frontiers in Oncology*, **2013**, 3, 231	5.3	102
61	Boosting anticancer vaccines: Too much of a good thing?. *OncoImmunology*, **2013**, 2, e25032	7.2	5
60	Vaccine-instructed intratumoral IFN-enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation. *Cancer Research*, **2013**, 73, 4641-52	10.1	15
59	Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. *MAbs*, **2013**, 5, 34-46	6.6	29
58	Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. *OncoImmunology*, **2013**, 2, e24520	7.2	33

57	Tumor-targeting vaccination instructs graft-vs.-tumor immune responses. *OncoImmunology*, **2013**, 2, e25996	7.2	3
56	The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. *OncoImmunology*, **2013**, 2, e22058	7.2	87
55	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. *Blood*, **2013**, 122, 680-680	2.2	3
54	Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer. *Cancer Immunology, Immunotherapy*, **2012**, 61, 2377-8	7.4	1
53	Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. *Cancer Immunology, Immunotherapy*, **2012**, 61, 453-68	7.4	21
52	Won't you come on in? How to favor lymphocyte infiltration in tumors. *OncoImmunology*, **2012**, 1, 986-988	7.2	21
51	Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. *Cancer Research*, **2012**, 72, 2746-56	10.1	349
50	Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. *Journal of Immunology*, **2012**, 188, 2687-94	5.3	117
49	Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer. *Clinical Cancer Research*, **2011**, 17, 1012-23	12.9	24
48	Concurrent allorecognition has a limited impact on posttransplant vaccination. *Journal of Immunology*, **2011**, 186, 1361-8	5.3	5
47	iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. *PLoS ONE*, **2010**, 5, e8646	3.7	51
46	Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. *Cancer Research*, **2010**, 70, 3505-14	10.1	22
45	Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. *Journal of Neuroimmunology*, **2010**, 220, 52-63	3.5	75
44	Modulators of arginine metabolism support cancer immunosurveillance. *BMC Immunology*, **2009**, 10, 1	3.7	55
43	Characterization of preclinical models of prostate cancer using PET-based molecular imaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 1245-55	8.8	4
42	Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. *Trends in Immunology*, **2008**, 29, 235-41	14.4	31
41	Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma. *Molecular Cancer Therapeutics*, **2008**, 7, 3859-66	6.1	24
40	Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. *Cancer Research*, **2008**, 68, 292-300	10.1	56

39	Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. *Prostate*, **2008**, 68, 1105-15	4.2	41
38	Prolonged exposure of dendritic cells to maturation stimuli favors the induction of type-2 cytotoxic T lymphocytes. *European Journal of Immunology*, **2006**, 36, 3157-66	6.1	6
37	Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses. *Journal of Immunology*, **2006**, 177, 2131-7	5.3	19
36	Autoimmune Disease: Pathogenesis **2005**,		1
35	Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. *Blood*, **2005**, 105, 3596-604	2.2	14
34	Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. *European Journal of Immunology*, **2005**, 35, 66-75	6.1	68
33	The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration. *Journal of Immunology*, **2005**, 174, 3317-25	5.3	20
32	Nitric oxide confers therapeutic activity to dendritic cells in a mouse model of melanoma. *Cancer Research*, **2004**, 64, 3767-71	10.1	45
31	Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. *Cancer Research*, **2004**, 64, 7150-5	10.1	63
30	Dendritic cell activation kinetics and cancer immunotherapy. *Journal of Immunology*, **2004**, 172, 2727-8	5.3	4
29	Cellular microchimerism as a lifelong physiologic status in parous women: an immunologic basis for its amplification in patients with systemic sclerosis. *Arthritis and Rheumatism*, **2003**, 48, 1109-16		28
28	Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. *Cancer Research*, **2003**, 63, 3688-94	10.1	58
27	Autoantibodies against a 72-kDa ductal cell membrane glycoprotein in a patient affected by Sjögren's syndrome and gastric MALT lymphoma. *Annals of Hematology*, **2002**, 81, 597-602	3	4
26	Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells. *Cancer Research*, **2002**, 62, 1116-22	10.1	12
25	Apoptosis, cross-presentation, and the fate of the antigen specific immune response. *Apoptosis: an International Journal on Programmed Cell Death*, **2000**, 5, 307-14	5.4	28
24	Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. *Journal of Immunology*, **2000**, 165, 2651-6	5.3	106
23	Thymoma associated with systemic lupus erythematosus and immunologic abnormalities. *Lupus*, **2000**, 9, 151-4	2.6	19
22	Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. *Journal of Experimental Medicine*, **1999**, 189, 871-6	16.6	184

21	Cancer immunotherapy: synthetic and natural peptides in the balance. *Trends in Immunology*, **1999**, 20, 457-62		22
20	Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells. *Journal of Leukocyte Biology*, **1999**, 66, 247-51	6.5	24
19	Immunotherapy: natural versus synthetic peptides. *Trends in Immunology*, **1998**, 19, 98		6
18	Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. *Human Gene Therapy*, **1998**, 9, 1335-44	4.8	23
17	Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. *European Journal of Immunology*, **1996**, 26, 1851-9	6.1	46
16	Engineered APCs for tumor immunotherapy. *Trends in Immunology*, **1996**, 17, 198		
15	Clustering of B and T epitopes within short sequence regions of the nicotinic acetylcholine receptor. *Scandinavian Journal of Immunology*, **1995**, 41, 135-40	3.4	9
14	Mechanisms by which the I-ABM12 mutation influences susceptibility to experimental myasthenia gravis: a study in homozygous and heterozygous mice. *Scandinavian Journal of Immunology*, **1995**, 42, 215-25	3.4	30
13	Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. *European Journal of Immunology*, **1995**, 25, 1154-62	6.1	106
12	Preferential pairing of T and B cells for production of antibodies without covalent association of T and B epitopes. *European Journal of Immunology*, **1994**, 24, 799-804	6.1	18
11	In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. *European Journal of Immunology*, **1994**, 24, 2691-8	6.1	41
10	Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. *Cancer Letters*, **1994**, 85, 211-6	9.9	25
9	Autoimmunity Against the Nicotinic Acetylcholine Receptor and the Presynaptic Calcium Channel at the Neuromuscular Junction. *E&M Endocrinology and Metabolism*, **1994**, 151-189		
8	Myasthenia gravis: recognition of a human autoantigen at the molecular level. *Trends in Immunology*, **1993**, 14, 363-8		96
7	T helper function of CD4+ cells specific for defined epitopes on the acetylcholine receptor in congenic mouse strains. *Journal of Autoimmunity*, **1992**, 5, 27-46	15.5	9
6	Molecular mimicry among human autoantigens. *Trends in Immunology*, **1991**, 12, 46-7		15
5	Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors. *European Journal of Immunology*, **1991**, 21, 2303-10	6.1	52
4	Impairment of lymphocyte suppressive system in recent onset insulin-dependent diabetes mellitus. Correlation with blood glucose and serum insulin levels. *Acta Diabetologica Latina*, **1989**, 26, 257-63		1

3	Use of Synthetic Peptides and High Affinity Protein Ligands for Structural Studies of Central and Peripheral Nicotinic Receptors **1989**, 291-309	5
2	Cimetidine Treatment in Hyper-IgM Hypogammaglobulinemia. *JAMA - Journal of the American Medical Association*, **1987**, 258, 1892-1892	27.4
1	Autoimmune Disease: Pathogenesis	1